These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 27432089

  • 1. Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis.
    Beyazit Y, Sayilir A, Tanoglu A, Kekilli M, Kocak E, Ekiz F, Tas A.
    Intern Med; 2016; 55(14):1831-6. PubMed ID: 27432089
    [Abstract] [Full Text] [Related]

  • 2. Plasma thrombin-activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis.
    Sayilir A, Beyazit Y, Yesil Y, Albayrak M, Ekiz F, Celik T, Suvak B, Torun S, Ibiş M.
    Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):498-504. PubMed ID: 22230218
    [Abstract] [Full Text] [Related]

  • 3. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [Abstract] [Full Text] [Related]

  • 4. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.
    Owczarek D, Undas A, Foley JH, Nesheim ME, Jabłonski K, Mach T.
    J Crohns Colitis; 2012 Feb; 6(1):13-20. PubMed ID: 22261523
    [Abstract] [Full Text] [Related]

  • 5. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission.
    Erdoğan M, Özbek M, Akbal E, Üreten K.
    Turk J Med Sci; 2019 Oct 24; 49(5):1381-1385. PubMed ID: 31549496
    [Abstract] [Full Text] [Related]

  • 6. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
    Akinci B, Comlekci A, Ali Ozcan M, Demir T, Yener S, Demirkan F, Yuksel F, Yesil S.
    Endocr J; 2007 Feb 24; 54(1):45-52. PubMed ID: 17090955
    [Abstract] [Full Text] [Related]

  • 7. Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome.
    Pang H, Zhang C, Liu F, Gong X, Jin X, Su C.
    Med Intensiva; 2017 Nov 24; 41(8):475-482. PubMed ID: 28038785
    [Abstract] [Full Text] [Related]

  • 8. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
    Bridge KI, Bollen L, Zhong J, Hesketh M, Macrae FL, Johnson A, Philippou H, Scott DJ, Gils A, Ariёns RAS.
    J Thromb Haemost; 2017 Nov 24; 15(11):2218-2225. PubMed ID: 28834317
    [Abstract] [Full Text] [Related]

  • 9. Thrombin-activatable fibrinolysis inhibitor (TAFI) is enhanced in major trauma patients without infectious complications.
    Relja B, Lustenberger T, Puttkammer B, Jakob H, Morser J, Gabazza EC, Takei Y, Marzi I.
    Immunobiology; 2013 Apr 24; 218(4):470-6. PubMed ID: 22749979
    [Abstract] [Full Text] [Related]

  • 10. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
    Akinci B, Demir T, Comlekci A, Yener S, Ozcan MA, Karaoglu O, Yuksel F, Secil M, Yesil S.
    Med Princ Pract; 2011 Apr 24; 20(1):23-8. PubMed ID: 21160209
    [Abstract] [Full Text] [Related]

  • 11. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP, Schulman S, An SS, Greenfield RS, Blombäck M.
    Scand J Clin Lab Invest; 2004 Apr 24; 64(8):745-51. PubMed ID: 15719893
    [Abstract] [Full Text] [Related]

  • 12. Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.
    Yaoita N, Satoh K, Satoh T, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Miyata S, Kawamura T, Horiuchi H, Fukumoto Y, Shimokawa H.
    Arterioscler Thromb Vasc Biol; 2016 Jun 24; 36(6):1293-301. PubMed ID: 27102961
    [Abstract] [Full Text] [Related]

  • 13. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G, Vikerfors A, Woodhams B, Adam M, Bremme K, Holmström M, Ågren A, Eelde A, Bruzelius M, Svenungsson E, Antovic A.
    Thromb Res; 2017 Oct 24; 158():168-173. PubMed ID: 28669410
    [Abstract] [Full Text] [Related]

  • 14. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD).
    Verdú J, Marco P, Benlloch S, Sanchez J, Lucas J.
    Thromb Haemost; 2006 Mar 24; 95(3):585-6. PubMed ID: 16525595
    [No Abstract] [Full Text] [Related]

  • 15. Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal Japanese population.
    Akatsu H, Ishiguro M, Ogawa N, Kanesaka T, Okada N, Yamamoto T, Campbell W, Okada H.
    Microbiol Immunol; 2007 Mar 24; 51(5):507-17. PubMed ID: 17579260
    [Abstract] [Full Text] [Related]

  • 16. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug 24; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 17. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
    Guimarães AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC.
    Br J Haematol; 2004 Mar 24; 124(5):659-65. PubMed ID: 14871254
    [Abstract] [Full Text] [Related]

  • 18. Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients.
    Bavbek N, Ceri M, Akdeniz D, Kargili A, Duranay M, Erdemli K, Akcay A, Guz G.
    Ren Fail; 2014 Jun 24; 36(5):743-7. PubMed ID: 24580410
    [Abstract] [Full Text] [Related]

  • 19. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
    Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP.
    Thromb Haemost; 2003 Jul 24; 90(1):92-100. PubMed ID: 12876631
    [Abstract] [Full Text] [Related]

  • 20. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
    Santamaría A, Oliver A, Borrell M, Mateo J, Belvis R, Martí-Fábregas J, Ortín R, Tirado I, Souto JC, Fontcuberta J.
    Stroke; 2003 Oct 24; 34(10):2387-91. PubMed ID: 12947154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.